Emerging Research and News in Prostate Cancer Imaging — March 2025
Catch up on the most-well viewed prostate imaging content in March 2025.
Touching on a variety of topics in prostate cancer imaging, ranging from monitoring of prostate MRI exams to reduce contrast use to a new meta-analysis on AI and bpMRI for csPCa detection and FDA approval of Gozellix for the preparation of the PSMA PET agent 68Ga gozetotide, here are the top five most well-viewed prostate imaging content from Diagnostic Imaging for March 2025.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
